NASDAQ · PEPGHealthcarePharmaceuticals

PepGen news

$2.34−9.65%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About PepGen

No recent articles focused on PepGen.

Also mentions PEPG

Articles that tag PEPG but are mainly about other companies.

Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Outlook

GlobeNewswire Inc.Apr 21, 4:31 AM ET▲ Positive

Mentioned as an emerging biotechnology firm actively developing novel peptide platforms and expanding PDC applications beyond cancer treatment.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology